Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin Add-on to Rapid-acting Insulin Secretagogue in Japanese T2DM Patients
NCT01517321Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Sitagliptin with Placebo (2 arms). Primary endpoint: Incidences of adverse experiences and change in vital sign, safety lab etc. as parameters of safety and tolerability at 52 weeks. Status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01517321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01517321.